Bevacizumab and ovarian cancer

Therapeutic Advances in Medical Oncology

Volumn 5, Issue 2, 2013, Pages 133-141

  Garcia, Agustin ^a   Singh, Harpreet ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

bevacizumab; combination therapy; ovarian cancer; progression free survival; single agent therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; TOPOTECAN;

ABSCESS; ADD ON THERAPY; ALLERGIC REACTION; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR VASCULARIZATION; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT;

EID: 84877902627     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012467661     Document Type: Review

References (52)

1. Agarwal R. Kaye S. (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502–516.
2. Aghajanian C. Finkler N. Rutherford T. Smith D. Yi J. Parmar L. et al. (2011) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) (LBA5007). J Clin Oncol 29(Suppl. Abstracts): LBA5007.
3. Alberts D. Liu P. Hannigan E. O'Toole R. Williams S. Young J. et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1955.
4. Armstrong D. Bundy B. Wenzel L. Huang H. Baergen R. Lele S. et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43.
5. Bello l. Carrabba G. Giussani C. Lucini V. Cerutti F. Scaglione F. et al. (2001) Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61: 7501–7506.
6. Bookman M. (2009) Trials with impact on clinical management: first line. Int J Gynecol Cancer 19(Suppl. 2): S55–S62.
7. Bookman M. Darcy K. Clarke-Pearson D. Boothby R. Horowitz I. (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21: 283–290.
8. Burger R. Brady M. Bookman M. Fleming G. Monk B. Huang H. et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473–2483.
9. Burger R. Sill M. Monk B. Greer B. Sorosky J. (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 25: 5165–5171.
10. Byrne A. Ross L. Holash J. Nakanishi M. Hu L. Hofmann J. et al. (2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9: 5721–5728.
11. Cannistra S. Matulonis U. Penson R. Hambleton J. Dupont J. Mackey H. et al. (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180–5186.
12. Cohn D. Kim K. Resnick K. O'Malley D. Straughn J. Jr. (2011) At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 29: 1247–1251.
13. Escudier B. Pluzanska A. Koralewski P. Ravaud A. Bracarda S. Szczylik C. et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111.
14. Friedman H. Prados M. Wen P. Mikkelsen T. Schiff D. Abrey L. et al. (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733–4740.
15. Garcia A. Hirte H. Fleming G. Yang D. Tsao-Wei D. Roman L. et al. (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26: 76–82.
16. Garcia A. Sill M. Lankes H. Godwin A. Mannel R. Armstrong D. et al. (2012) A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 124: 569–574.
17. Gordon A. Finkler N. Edwards R. Garcia A. Crozier M. Irwin D. et al. (2005) Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15: 785–792.
18. Gordon M. Matei D. Aghajanian C. Matulonis U. Brewer M. Fleming G. et al. (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER 2 activation status. J Clin Oncol 24: 4324–4332.
19. Hanahan D. Bergers G. Bergsland E. (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105: 1045–1047.
20. Hashimoto K. Man S. Xu P. Cruz-Munoz W. Tang T. Kumar R. et al. (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9: 996–1006.
21. Heintz A. Odicino F. Maisonneuve P. Quinn M. Benedet J. Creasman W. et al. (2006) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl. 1): S161–S192.
22. Hollingsworth H. Kohn E. Steinberg S. Rothenberg M. Merino M. (1995) Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147: 33–41.
23. Hurwitz H. Fehrenbacher L. Novotny W. Cartwright T. Hainsworth J. Heim W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342.
24. Jain R. (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19(Suppl. 3): S7–S16.
25. Katsumata N. Yasuda M. Takahashi F. Isonishi S. Jobo T. Aoki D. et al. (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374: 1331–1338.
26. Klement G. Baruchel S. Rak J. Man S. Clark K. Hicklin D. et al. (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15–R24.
27. Kudoh K. Takano M. Kouta H. Kikuchi R. Kita T. Miyamoto M. et al. (2011) Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol 122: 233–237.
28. Lesnock J. Farris C. Krivak T. Smith K. Markman M. (2011) Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol 122: 473–478.
29. Lin Y.S. Nguyen C. Mendoza J.L. Escandon E. Fei D. Meng Y.G. et al. (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288: 371–378.
30. McGonigle K. Muntz H. Vuky J. Paley P. Veljovich D. Greer B. et al. (2011) Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 117: 3731–3740.
31. McGuire W. Hoskins W. Brady M. Kucera P. Partridge E. Look K. et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1–6.
32. Markman M. Bundy B. Alberts D. Fowler J. Clark-Pearson D. Carson L. et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001–1007.
33. Markman M. Rothman R. Hakes T. Reichman B. Hoskins W. Rubin S. et al. (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389–393.
34. Merritt W. Nick A. Carroll A. Lu C. Matsuo K. Dumble M. et al. (2010) Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9: 985–995.
35. Micha J. Goldstein B. Rettenmaier M. Genesen M. Graham C. Bader K. et al. (2007) A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17: 771–776.
36. National Cancer Institute (2012) Carboplatin and paclitaxel with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer. linicalTrials.gov Identifier: NCT00565851. Available at: http://clinicaltrials.gov/ct2/show/NCT00565851?term=NCT00565851&rank=1
37. O'Malley D. Richardson D. Rheaume P. Salani R. Eisenhauer E. Mccann G. et al. (2011) Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 121: 269–272.
38. Penson R. Dizon D. Cannistra S. Roche M. Krasner C. Berlin S. et al. (2010) Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 28: 154–159.
39. Perren T. Swart A. Pfisterer J. Ledermann J. Pujade-Lauraine E. Kristensen G. et al. for the ICON 7 Investigators (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484–2496.
40. Piccart M. Bertelsen K. James K. Cassidy J. Mangioni C. Simonsen E. et al. (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699–708.
41. Posadas E. Liel M. Kwitkowski V. Minasian L. Godwin A. Hussain M. et al. (2007) A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109: 1323–1330.
42. Pujade-Lauraine E. Hilpert F. Weber B. Reuss A. Poveda A. Kristensen G. et al. (2012) AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) (LBA5002). J Clin Oncol 30(Suppl. Abstracts): LBA5002.
43. Rowan K. (2009) Intraperitoneal therapy for ovarian cancer: why has it not become standard? J Natl Cancer Institute 101: 775–777.
44. Sánchez-Muñoz A. Mendiola C. Pérez-Ruiz E. Rodríguez-Sánchez C. Jurado J. Alonso-Carrión L. et al. (2010) Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology 79: 98–104.
45. Sandler A. Gray R. Perry M. Brahmer J. Schiller J. Dowlati A. et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell cancer. N Engl J Med 355: 2542–2550.
46. Schilder R. Pathak H. Lokshin A. Holloway R. Alvarez R. Aghajanian C. et al. (2009) Phase II trial of single-agent cetuximab in atients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 113: 21–27.
47. Schilder R. Sill M. Chen X. Darcy K. Decesare S. Lewandowski G. et al. (2005) Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin Cancer Res 11: 5539–5548.
48. Schilder R. Sill M. Lee R. Shaw T. Senterman M. Klein-Szanto A. et al. (2008) Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 26: 3418–3425.
49. Shen G. Ghazizadeh M. Kawanami O. Shimizu H. Jin E. Araki T. et al. (2000) Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83: 196–203.
50. Siegel R. Naishadham D. Jemal A. (2012) Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 62: 21153. Epub ahead of print 17 Sept 2012. DOI: 10.3322/caac.21153.
51. Tillmanns T.D. Lowe M.P. Walker M.S. Stepanski E.J. Schwartzberg L.S. (2012) Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol. Epub ahead of print in September.
52. Vergote I. Tropé C. Amant F. Kristensen G. Ehlen T. Johnson N. et al. (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363: 943–953.